JP2024536479A - 腎臓疾患の治療 - Google Patents

腎臓疾患の治療 Download PDF

Info

Publication number
JP2024536479A
JP2024536479A JP2024522027A JP2024522027A JP2024536479A JP 2024536479 A JP2024536479 A JP 2024536479A JP 2024522027 A JP2024522027 A JP 2024522027A JP 2024522027 A JP2024522027 A JP 2024522027A JP 2024536479 A JP2024536479 A JP 2024536479A
Authority
JP
Japan
Prior art keywords
patient
egfr
injection
cells
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536479A5 (https=
Inventor
ティモシー エー． ベルトラム，
ディーパク ジャイン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2024536479A publication Critical patent/JP2024536479A/ja
Publication of JP2024536479A5 publication Critical patent/JP2024536479A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
JP2024522027A 2021-10-14 2022-10-14 腎臓疾患の治療 Pending JP2024536479A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163255885P 2021-10-14 2021-10-14
US63/255,885 2021-10-14
US202263307801P 2022-02-08 2022-02-08
US63/307,801 2022-02-08
US202263321204P 2022-03-18 2022-03-18
US63/321,204 2022-03-18
PCT/US2022/078153 WO2023064925A1 (en) 2021-10-14 2022-10-14 Treatment of kidney disease

Publications (2)

Publication Number Publication Date
JP2024536479A true JP2024536479A (ja) 2024-10-04
JP2024536479A5 JP2024536479A5 (https=) 2025-10-15

Family

ID=85988933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522027A Pending JP2024536479A (ja) 2021-10-14 2022-10-14 腎臓疾患の治療

Country Status (8)

Country Link
US (1) US20250009803A1 (https=)
EP (1) EP4415729A4 (https=)
JP (1) JP2024536479A (https=)
KR (1) KR20240110801A (https=)
AU (1) AU2022362077A1 (https=)
CA (1) CA3233866A1 (https=)
MX (1) MX2024004355A (https=)
WO (1) WO2023064925A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106530A1 (en) * 2023-11-13 2025-05-22 Butler Emily Characteristics of enriched heterogeneous renal cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020266168A1 (en) * 2019-05-02 2021-12-02 ProKidney IPCo, LLC Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies

Also Published As

Publication number Publication date
WO2023064925A1 (en) 2023-04-20
US20250009803A1 (en) 2025-01-09
CA3233866A1 (en) 2023-04-20
KR20240110801A (ko) 2024-07-16
EP4415729A4 (en) 2025-08-27
WO2023064925A8 (en) 2024-04-11
AU2022362077A1 (en) 2024-05-02
EP4415729A1 (en) 2024-08-21
MX2024004355A (es) 2024-06-21

Similar Documents

Publication Publication Date Title
US12350292B2 (en) Bioactive renal cells for the treatment of chronic kidney disease
KR20190084207A (ko) 지방 조직 유래의 중간엽 기질 세포 조정 배지 및 이것의 제조 및 사용 방법
US20120276067A1 (en) Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same
Lacy et al. Allergic interstitial pancreatitis in rats injected with guinea pig anti-insulin serum
AU2023203923A1 (en) Bioactive renal cells for the treatment of chronic kidney disease
Young et al. Erosion of transplantation tolerance after infection
Khalili et al. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period
CN114206107A (zh) 用于产生肝细胞的方法和组合物
JP2024536479A (ja) 腎臓疾患の治療
Stavas et al. Renal autologous cell therapy to stabilize function in diabetes-related chronic kidney disease: corroboration of mechanistic action with cell marker analysis
CN111494407A (zh) 海藻糖在制备用于减轻缺血再灌注诱导的急性肾损伤相关病症的药物中的用途
CN110229215A (zh) 一种药物缓释多肽水凝胶及其制备方法和用途
US20200289574A1 (en) Augmentation of fertility by platelet rich plasma
WO2018220442A2 (en) Stromal stem cell therapeutics and methods of use
HK40113884A (zh) 肾脏疾病的治疗
CN118354777A (zh) 肾脏疾病的治疗
Cheng et al. Combination therapy with human amniotic epithelial cells and hyaluronic acid promotes immune balance recovery in type 1 diabetic rats through local engraftment
Petrulienė et al. Prediction of resistance to erythropoiesis stimulating agent therapy in hemodialysis patients
Moon et al. High mortality and limited regenerative response in a rabbit model of major hepatectomy with platelet-rich plasma injection
TW201919665A (zh) 治療及預防急性肝衰竭的方法
EP4601661A1 (en) Scd2+ stromal cells for treating diabetic kidney disease
CN119662531A (zh) 一种工程化血小板及其制备方法与其在1型糖尿病中的应用
Woziwodzka et al. Light chain deposition disease with concurrent myeloma multiplex-a successful treatment of AKI induced by lambda FLC
WO2022176735A1 (ja) 糖尿病の予防及び／又は治療剤
Irazabal et al. Mesenchymal Stem Cell–Based Therapy for Chronic Kidney Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006